Patrick K, Lau W, Gassas A, McDougall E, Doyle J, Ali M, Krueger J, Courtney S, Armstrong C, Egeler R M, Schechter T
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
Bone Marrow Transplant. 2015 Apr;50(4):536-9. doi: 10.1038/bmt.2014.309. Epub 2015 Jan 26.
Major ABO incompatible BM transplantation carries a risk of acute haemolysis. Red cell depletion reduces this risk but not all incompatible RBC (iRBCs) are removed and in children the residual volume can be significant relative to body weight. We sought to determine the volume of iRBCs that can be safely given to children. All patients receiving fresh BM from a donor with a major ABO blood group mismatch between January 2000 and July 2013 at the Hospital for Sick Children, Toronto, were included. Seventy-eight patients were identified. The median volume of iRBCs transfused was 1.6 mL/kg (range 0.1-10.6 mL/kg). Thirty-five patients had minor haemolytic events and five patients had clinically significant adverse events. Two patients, who received 3.66 and 3.9 mL iRBCs/kg, developed renal impairment and in one case hypoxia and hyperbilirubinaemia. One patient had mild hypotension that resolved with i.v. fluid. Two patients developed hypotension secondary to sepsis and unrelated to BM infusion. Although signs of haemolysis occur, with appropriate hydration and monitoring of renal function, clinically significant adverse events related to the infusion of ABO incompatible BM are rare, and, in this study, were only seen in patients receiving >3 mL/kg of iRBCs per kg.
主要ABO血型不合的骨髓移植存在急性溶血风险。去除红细胞可降低此风险,但并非所有不相容的红细胞(iRBCs)都能被清除,且在儿童中,相对于体重而言,残留量可能相当可观。我们试图确定可安全给予儿童的iRBCs量。纳入2000年1月至2013年7月期间在多伦多病童医院接受来自主要ABO血型不匹配供体新鲜骨髓的所有患者。共识别出78例患者。输注的iRBCs中位数体积为1.6 mL/kg(范围0.1 - 10.6 mL/kg)。35例患者发生轻微溶血事件,5例患者出现具有临床意义的不良事件。两名分别接受3.66和3.9 mL iRBCs/kg的患者出现肾功能损害,其中一例出现缺氧和高胆红素血症。一名患者出现轻度低血压,经静脉补液后缓解。两名患者因败血症继发低血压,与骨髓输注无关。尽管出现溶血迹象,但通过适当补液和监测肾功能,与输注ABO血型不合骨髓相关的具有临床意义的不良事件很少见,在本研究中,仅在接受每千克体重>3 mL/kg iRBCs的患者中出现。